Category survey

Knockin Mouse Models of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Is HSF1 the key in mediating Hsp90 inhibitor effect in AD? Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Role of PS1 in neurodegeneration Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Tranthyretins Regulatory Role in Beta-Amyloid Aggregation and Toxicity Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

SYNAPTIC REGULATION OF ERK-MEDIATED AMYLOID-BETA METABOLISM Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Identification of Old-Age-Associated Alzheimers Disease Drug Targets Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Water-soluble Abeta and its role in Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Human induced neuronal stem cell models of familial Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Hippocampal Synaptic Structure Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

In Vivo Imaging Alzheimers Disease Pathology with 2-Photon/Lifetime Microscopy Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Mechanisms of brain rejuvenation Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Mitochondrial ATP Synthase Dysfunction and Synaptic Stress in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Proteostasis in the aging and Alzheimers disease brain: are the ATases novel targets? Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Understanding Alzheimers Disease in the Context of the Aging Brain Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Decoding the role of diverse astrocyte populations in aging and AD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

The role of aging-associated microRNAs in Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Short Sleep: Locus Coeruleus Metabolics and the Temporal Progression of Alzheimers Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Interrogating the link between aging and AD with temporally-controlled transgenes Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

The role of TREM1 signaling in the development of Alzheimer’s disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Demystifying Microglia in Aging and Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

mGlu Allosteric Modulation in Neurodegenerative Diseases Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

BRI2 Familial British and Danish Dementias and Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Tyrosine phosphorylation in Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Molecular interplay between A?, tau and mTOR: Mechanisms of neurodegeneration Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Investigating the RhoA/ROCK pathway for the treatment of Alzheimers disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Voltage-Dependent Anion Channel and Neurodegeneration in Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Proteostasis and secondary proteinopathy in AD and FTD Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Modeling aerobic exercise regimens: prevention and amelioration of amyloid pathologies and cognitive impairment Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Neuroinflammatory and cognitive consequences of losing cholinergic anti-inflammatory tone in the forebrain Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

APP as a common denominator for Alzheimers disease and osteoporosis Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Influence of systemic immune inflammation upon the tauopathy phenotype in mouse models Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Role of LIPL-4 in lysosomal lipolysis and aging Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Presenilin Variants in the Modulation of Hippocampal Neurogenesis Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Calcineurin and inflammatory signaling processes in aging and Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Apolipoprotein E in Alzheimers Disease: Molecular Mechanism Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Molecular pathways leading to neurodegeneration in vivo Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Investigating the neuroinflammatory role of RIP1 kinase Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Mouse Cell Type-Specific Brain Mapping in Health and Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

DnaJ co-chaperones which modify tau aggregation and neurodegeneration Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

BMP9 as a juvenile protective factor in cognitive aging Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Gamma-secretase cleavage of the p75 receptor Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Pathophysiology of APP in vivo Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Proteomic reconstructive microscopy of healthy and diseased dendrites Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Role of the Innate Immune System in Aging and Development of Alzheimers Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Actions of Nuclear Receptors on TREM2+ myeloid cells and microglia in AD brain Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Converting Alzheimers reactive astrocytes into functional neurons Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

GDE and Neurodegenerative Diseases Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Misfolded protein clearance enhancers for Alzheimers therapy Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Tau Oligomer Platform Validation Using Lead Series Candidate in htau Mice Investments > €500k United States of America Alzheimer’s disease & other dementias 2016    

Brain Neurotropic Growth Factor Delivery to Prevent and Treat Alzheimer’s Disease Investments > €500k United States of America Alzheimer’s disease & other dementias 2016